LATENT VIEW ANALYTICS
|
|
BOM : 543398     NSE : LATENTVIEW     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Average [Stock is fairly valued] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Neutral
Price Momentum : Downward Pledged Shares : NA |
Oct 07,2024 |
Price(EOD): ₹ 455.90
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Business Support |
MCap: ₹ 9,391.54 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
LATENT VIEW ANALYTICS | -3.6% | -4% | 14.5% |
SYNGENE INTERNATIONAL | -3.4% | -4.3% | 6.8% |
SUN PHARMA ADVANCED RESEARCH COMPANY | -6.4% | -9.9% | -10.1% |
JUST DIAL | -0.9% | -9.4% | 65.1% |
DREAMFOLKS SERVICES | -2.6% | -5.2% | -7.1% |
EKI ENERGY SERVICES | -6.3% | -11.7% | -34.5% |
FUNDAMENTAL ANALYSIS OF LATENT VIEW ANALYTICS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF LATENT VIEW ANALYTICS
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
57.02
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 164.71 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] 6.87
P/B Calculated based on Book Value of Rs 1,367.85 Cr
[Latest Year - Mar2024 - Consolidated Results ] 13.98
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 671.89 Cr
[Latest Qtr - Jun2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
53% -19% -21% |
SHARE PRICE MOMENTUM OF LATENT VIEW ANALYTICS
LATENT VIEW ANALYTICS vs SENSEX
DEBT OF LATENT VIEW ANALYTICS
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0 0 0 - |
0 0 0 - |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF LATENT VIEW ANALYTICS
Pledged Promoter Shares |
NA | |
---|---|---|
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF LATENT VIEW ANALYTICS
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
4.22% -5.27% -1.74% -13.95% |
21.13% 36.3% 21.77% 18.47% |
QtrlyTrend |
2 | |
Latest Qtr: Jun2024 | ||
Quarterly Result Analysis → |
LATENT VIEW ANALYTICS related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
S&P BSE IT | -0.7% | -1.4% | 32.5% |
S&P BSE 250 SMALLCAP | -4.6% | -4.1% | 41.1% |
S&P BSE 400 MIDSMALLCAP | -5% | -3.5% | 42.9% |
S&P BSE MIDSMALLCAP | -5.1% | -3.9% | 44.8% |
S&P BSE SMALL CAP | -5.2% | -3.7% | 44.1% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY SMALLCAP250 | -4.8% | -4.4% | 43.2% |
NIFTY MID SMALL400 | -4.9% | -3.4% | 41.4% |
NIFTY500 MULTICAP 50:25:25 | -5.2% | -2.8% | 36.7% |
NIFTY 500 | -5.3% | -2.4% | 34.1% |
You may also like the below Video Courses
FAQ about LATENT VIEW ANALYTICS
Is LATENT VIEW ANALYTICS good for long term investment?
As on Oct 07,2024, the Fundamentals of LATENT VIEW ANALYTICS look Strong and hence it may be good for long term investment! See Financial Performance of LATENT VIEW ANALYTICS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is LATENT VIEW ANALYTICS UnderValued or OverValued?
As on Oct 07,2024, LATENT VIEW ANALYTICS is Fairly Valued based on the estimates of intrinsic value and investors may wait for the buying opportunity once it becomes under valued!What is the Intrinsic Value of LATENT VIEW ANALYTICS ?
As on Oct 07,2024, the Intrinsic Value of LATENT VIEW ANALYTICS is Rs. 563.32 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 298.71
Fair Value [Median EV / Sales Model] : Rs. 563.32
Fair Value [Median Price / Sales Model] : Rs. 579.59
Estimated Median Fair Value of LATENT VIEW ANALYTICS : Rs. 563.32
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.